A long-term study of istradefylline safety and efficacy in patients with Parkinson disease

Clinical Neuropharmacology
Tomoyoshi KondoJapanese Istradefylline Study Group

Abstract

Istradefylline is a selective adenosine A2A receptor antagonist. We evaluated the safety and efficacy of istradefylline administered once daily for 52 weeks in Parkinson disease (PD) patients experiencing wearing-off symptoms on levodopa therapy. This was a phase 3, multicenter, open-label, long-term study in PD patients experiencing wearing-off who had previously completed a double-blind placebo-controlled clinical study of istradefylline in Japan. Istradefylline was administered for 52 weeks at a starting dosage of 20 mg/d, with or without dosage adjustment up to 40 mg/d. Safety was assessed using the incidence of treatment-emergent adverse events, and efficacy was assessed as the change in the daily off time. A total of 308 patients were included in this study. The most frequently reported treatment-emergent adverse events were nasopharyngitis (24.4%) and dyskinesia (21.4%). The mean change in the daily off time from day 1 was -0.65 hour in week 2, fluctuating between -0.71 and -0.04 hour until week 52 in patients who had previously taken placebo in the preceding double-blind study. The off time reduction from baseline of the double-blind study remained at similar levels between weeks 2 and 52 in patients who had previously ...Continue Reading

References

Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Azi H RajputOleh Hornykiewicz
Aug 13, 2003·Neurology·Robert A HauserUNKNOWN Istradefylline US-001 Study Group
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserPhilippe Lehert
Jul 12, 2005·Expert Opinion on Investigational Drugs·Peter Jenner
Jul 11, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Plamen GatevThomas Wichmann
Oct 4, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN Istradefylline 6002-US-013 Study Group
Mar 27, 2010·Parkinsonism & Related Disorders·Stewart FactorUNKNOWN Istradefylline 6002-US-007 Study Group
Jul 16, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Yoshikuni MizunoUNKNOWN Japanese Istradefylline Study Group
Oct 18, 2011·Parkinsonism & Related Disorders·Emmanuelle PourcherPhilip Chaikin
Dec 14, 2011·Expert Opinion on Pharmacotherapy·Ariane Park, Mark Stacy
Mar 14, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Yoshikuni MizunoUNKNOWN Japanese Istradefylline Study Group

❮ Previous
Next ❯

Citations

Dec 3, 2015·Expert Review of Neurotherapeutics·Ruxandra Julia Vorovenci, Angelo Antonini
Feb 3, 2016·Expert Opinion on Pharmacotherapy·Mitesh Lotia, Joseph Jankovic
Aug 22, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolJoaquim J Ferreira
Apr 29, 2015·Journal of Cellular Physiology·Dominik WolfAnna Maria Wolf
May 28, 2016·Neurodegenerative Disease Management·Maria Eliza Freitas, Susan H Fox
Jul 2, 2016·Journal of Neurochemistry·Rodrigo A Cunha
Oct 19, 2016·Lancet Neurology·Alberto Ascherio, Michael A Schwarzschild
Apr 12, 2017·The Journal of Pharmacy and Pharmacology·Jan Schmidt, Polonca Ferk
Apr 27, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jocelyn StockwellFrancisco S Cayabyab
Jul 1, 2017·Journal of Enzyme Inhibition and Medicinal Chemistry·Romain DurouxSaïd Yous
Jul 28, 2017·Chinese Medical Journal·Juan-Juan Du, Sheng-Di Chen
Mar 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxUNKNOWN Movement Disorder Society Evidence-Based Medicine Committee
Dec 23, 2017·Scientific Reports·Wataru SakoRyuji Kaji
Mar 9, 2018·Cell and Tissue Research·Hana YouJean-Christophe Corvol
Sep 29, 2018·Nature Reviews. Drug Discovery·Delphine CharvinOlivier Rascol
Sep 21, 2018·Expert Opinion on Pharmacotherapy·Margherita TortiFabrizio Stocchi
Nov 10, 2017·Current Opinion in Organ Transplantation·Eduardo Castillo-LeonPaolo Fiorina
Apr 12, 2019·Biomolecules·Fabio Del BelloWilma Quaglia
Jul 25, 2019·Current Pharmaceutical Design·Pobitra BorahPran Kishore Deb
Jan 10, 2017·Pharmaceuticals·Julia CastelloHeike Rebholz
Sep 8, 2017·Journal of Clinical Pharmacology·Mayumi MukaiMarc Cantillon
Mar 30, 2018·Frontiers in Psychiatry·Rafael Franco, Gemma Navarro
May 29, 2018·Parkinson's Disease·Carlos E ManteseCarlos R M Rieder
Jan 6, 2019·Neurochemical Research·Michelle Lima GarcezCarina Rodrigues Boeck
Jun 17, 2020·Molecular Imaging·Hamideh Zarrinmayeh, Paul R Territo
Apr 10, 2017·Journal of Neural Transmission·Marc Morissette, Thérèse Di Paolo
Jan 30, 2019·Oxidative Medicine and Cellular Longevity·Alex France M MonteiroLuciana Scotti
Mar 31, 2017·F1000Research·Wolfgang H Oertel
Aug 14, 2020·CNS Drugs·Paulina Gonzalez-LatapiSusan H Fox
Oct 20, 2017·Frontiers in Pharmacology·Caio M MassariFrancisco Ciruela

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Yoshikuni MizunoJapanese Istradefylline Study Group
Movement Disorders : Official Journal of the Movement Disorder Society
Robert A HauserIstradefylline 6002-US-013 Study Group
© 2021 Meta ULC. All rights reserved